Listing of Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound of the Formula:



wherein:

R^1 is selected from:

a) hydrogen,

b) aryl, heterocycle, C_3-C_{10} cycloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, and

c) C_1-C_6 alkyl, unsubstituted or substituted with 1 to 5 substituents selected from:

1) aryl, unsubstituted or substituted with 1 to 5 substituents selected from:

i) C_1-C_6 alkyl, unsubstituted or substituted with 1-3 fluoro,

ii) C_3-C_6 cycloalkyl,

iii) C_2-C_6 alkynyl,

iv) OR^{10},

v) aryl,

vi) heterocycle,

vii) CN, and

viii) halo;

2) heterocycle, unsubstituted or substituted with 1 to 5 substituents selected from:

i) C_1-C_6 alkyl, unsubstituted or substituted with 1-3 fluoro,

ii) $-OR^{10}$,

iii) aryl, and

iv) halo;

3) C_3-C_{10} cycloalkyl,

4) C_2-C_6 alkenyl,

5) C_2-C_6 alkynyl,

6) $-OR^{10}$,

7) $-S(O)_mR^{11}$,

8) $-NR^6-C(O)R^7$,

9) $-C(O)-N(R^6)(R^7)$,

10) -CN,

11) $-NR^6-C(O)-N(R^6)(R^7)$,

12) $-C(O)-OR^{10}$,

13) halo, and

14) $-N(R^6)(R^7)$;

R^2 is selected from:

a) $-NR^6-C(O)R^7$,

b) $-NR^6-S(O)_2R^7$, and

c) $-NR^6-S(O)_2-N(R^6)(R^7)$;

R^3 and R^4 are independently selected from:

hydrogen, aryl, heterocycle, halo, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_4 haloalkyl, $R^{10}O-$, $R^{11}S(O)_m-$, $R^6C(O)-NR^7-$, CN, $(R^6)(R^7)N-C(O)-(NR^6)-$, $(R^6)(R^7)-N-C(O)-$, $R^{10}C(O)-$, $R^{10}OC(O)-$, and $N(R^6)(R^7)$; or

wherein R^3 and R^4 are optionally joined to form a saturated or unsaturated ring, containing 0-3 heteroatoms, wherein said ring is phenyl, ~~pyridyl,~~ pyrimidinyl, pyrazinyl, thiophenyl, furanyl, imidazolyl, thiazolyl, oxazolyl, and triazolyl, ~~as well as~~ and partially saturated analogues thereof, said ring optionally substituted with one or more of:

aryl, heterocycle, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_2-C_6 alkynyl, $R^{10}O-$, $R^{11}S(O)_m-$, $R^6C(O)N\,R^7-$, $-R^6S(O)_2NR^7-$, $(R^6)(R^7)N-C(O)-$, CN, $R^{10}OC(O)-$, F, and $-N(R^6)(R^7)$;

R^6 and R^7 are independently selected from hydrogen, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, heterocycle, aryl, unsubstituted or substituted ~~withone~~ with one or more of:

a) C_1-C_4 alkyl,
b) C_1-C_4 alkoxy,
c) aryl or heterocycle,
d) halo,
e) $-OR^{10}$, and
f) $-N(R^{10})_2$;

wherein R^6 and R^7 may be joined to form a ring;

R^{10} is independently selected from hydrogen, C_1-C_6 alkyl, $-CF_3$, C_3-C_{10} cycloalkyl, benzyl, and aryl;

R^{11} is independently selected from C_1-C_6 alkyl, and aryl;

m is 0, 1, or 2;

or a ~~and~~ pharmaceutically acceptable salt ~~salts~~ and individual diastereomers thereof.

2. (Original) The compound according to Claim 1, wherein R^1 is $-CH_2$-aryl, unsubstituted or substituted with 1-3 substituents selected from: fluoro, chloro, bromo, iodo and methyl.

3. (Original) The compound according to Claim 1, wherein R^1 is benzyl, substituted with 1-3 fluoro.

4. (Original) The compound according to Claim 1, wherein R^1 is $-CH_2C(O)OR^{10}$.

5. (Original) The compound according to Claim 1, wherein R^1 is $-CH_2C(O)OC(CH_3)_3$.

6. (Original) The compound according to Claim 1, wherein R^1 is $-CH_2C(O)NHR^6$.

7. (Original) The compound according to Claim 1, wherein R^1 is $-CH_2C(O)NH(C_4$-C_{10} cycloalkyl).

8. (Original) The compound according to Claim 1, wherein R^1 is $-CH_2C(O)NH$-aryl.

9. (Original) The compound according to Claim 1, wherein R^2 is $-NR^6$-$S(O)_2R^7$.

10. (Original) The compound according to Claim 1, wherein R^3 is hydrogen.

11. (Currently Amended) The compound according to Claim 1, wherein R^3 and R^4 are joined to form a ring selected from: phenyl, ~~pyridyl,~~ pyrimidinyl and pyrazinyl.

12. (Canceled)

13. (Original) The compound according to Claim 1, wherein R^4 is bromo.

14. (Original) The compound according to Claim 1, wherein R^4 is $-C(O)OR^{10}$.

15. (Currently Amended) A compound selected from:



,



,


,


,


,


,


,


,



,



,



,



,

and pharmaceutically acceptable salts and individual diastereomers thereof.

16. (Currently Amended) A pharmaceutical composition which comprises a pharmaceutically acceptable ~~an~~ inert carrier and the compound of Claim 1.

17. (Canceled)

18. (Previously Amended) A method for treating, controlling, ameliorating or reducing the risk of headache in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of the compound of Claim 1.

19 24. (Canceled)

25. (Previously Presented) The method of claim 18, wherein the headache is migraine headache or cluster headache.